Pegylated IFN-α regulates hepatic gene expression through transient Jak/STAT activation

Journal of Clinical Investigation

Volumn 124, Issue 4, 2014, Pages 1568-1581

  Dill, Michael T ^a,b   Makowska, Zuzanna ^a   Trincucci, Gaia ^a   Gruber, Andreas J ^c   Vogt, Julia E ^a   Filipowicz, Magdalena ^a,b   Calabrese, Diego ^a   Krol, Ilona ^a   Lau, Daryl T ^d   Terracciano, Luigi ^e   Van Nimwegen, Erik ^c   Roth, Volker ^a   Heim, Markus H ^a,b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA INTERFERON; STAT PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; TRANSCRIPTION FACTOR;

ADAPTIVE IMMUNITY; ADULT; AGED; ARTICLE; BINDING SITE; BLOOD LEVEL; CELLULAR IMMUNITY; CLINICAL ARTICLE; COMPARATIVE STUDY; DRUG EFFICACY; FEMALE; GENE CONTROL; GENETIC TRANSCRIPTION; GENOTYPE; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; VIRUS HEPATITIS;

ADULT; AGED; ANTIVIRAL AGENTS; ENDOPEPTIDASES; FEMALE; GENE EXPRESSION; HEPATITIS C, CHRONIC; HUMANS; IMMUNITY, CELLULAR; INTERFERON-ALPHA; INTERFERON-STIMULATED GENE FACTOR 3, GAMMA SUBUNIT; JANUS KINASES; KINETICS; LIVER; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; STAT1 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84897561826     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI70408     Document Type: Article

References (53)

1. Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity. 2006;25(3):373-381. (Pubitemid 44354218)
2. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol. 2008;8(7):559-568. (Pubitemid 351913674)
3. Darnell JE, Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415-1421. (Pubitemid 24217131)
4. Song MM, Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem. 1998;273(52):35056-35062. (Pubitemid 29028206)
5. Larner AC, Chaudhuri A, Darnell JE, Darnell JE Jr. Transcriptional induction by interferon. New protein(s) determine the extent and length of the induction. J Biol Chem. 1986;261(1):453-459. (Pubitemid 16103967)
6. Sarasin-Filipowicz M, et al. α Interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol. 2009;29(17):4841-4851.
7. Hoofnagle JH, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human α interferon. A preliminary report. N Engl J Med. 1986;315(25):1575-1578. (Pubitemid 17055392)
8. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345(1):41-52. (Pubitemid 32634271)
9. Fried MW, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-982.
10. Manns MP, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-965. (Pubitemid 32913521)
11. Zeuzem S, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343(23):1666-1672.
12. Lindsay KL, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34(2):395-403. (Pubitemid 32702353)
13. Sarasin-Filipowicz M, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A. 2008;105(19):7034-7039. (Pubitemid 351754525)
14. Chen L, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology. 2005;128(5):1437-1444. (Pubitemid 40712193)
15. Asselah T, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut. 2008;57(4):516-524.
16. Feld JJ, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology. 2007;46(5):1548-1563. (Pubitemid 350155537)
17. Dill MT, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology. 2011;140(3):1021-1031.
18. Lau DT, et al. Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology. 2013;144(2):402-413.
19. Foster GR. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs. 2010;70(2):147-165.
20. Silva M, et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol. 2006;45(2):204-213.
21. Consortium F, et al. The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. Nat Genet. 2009;41(5):553-562.
22. Heinz S, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010;38(4):576-589.
23. Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol. 2008;26:535-584. (Pubitemid 351600385)
24. Hoshino K, et al. IkappaB kinase-alpha is critical for interferon-alpha production induced by Toll-like receptors 7 and 9. Nature. 2006;440(7086):949- 953.
25. Cheon H, Stark GR. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci U S A. 2009;106(23):9373-9378.
26. Muller M, et al. Complementation of a mutant cell line: central role of the 91 kDa polypeptide of ISGF3 in the interferon-alpha and -gamma signal transduction pathways. EMBO J. 1993;12(11):4221-4228. (Pubitemid 23302036)
27. Hao S, Baltimore D. The stability of mRNA influences the temporal order of the induction of genes encoding inflammatory molecules. Nat Immunol. 2009;10(3):281-288.
28. Wu X, Brewer G. The regulation of mRNA stability in mammalian cells: 2.0. Gene. 2012;500(1):10-21.
29. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology. 2000;118(2):346-355. (Pubitemid 30067508)
30. Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology. 2002;123(4):1070-1083.
31. Claassen MA, de Knegt RJ, Turgut D, Groothuismink ZM, Janssen HL, Boonstra A. Negative regulation of hepatitis C virus specific immunity is highly heterogeneous and modulated by pegylated interferon-alpha/ribavirin therapy. PLoS One. 2012;7(11):e49389.
32. Barnes E, et al. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology. 2002;36(3):743-754. (Pubitemid 34977187)
33. + T cell responses in patients with chronic hepatitis C undergoing peginterferon/ribavirin therapy correlate with faster, but not sustained, viral clearance. J Infect Dis. 2007;195(9):1315-1319.
34. Lanford RE, Guerra B, Lee H, Chavez D, Brasky KM, Bigger CB. Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. Hepatology. 2006;43(5):961-972. (Pubitemid 43724621)
35. Malakhova OA, et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J. 2006;25(11):2358-2367. (Pubitemid 44012219)
36. Fenner JE, et al. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat Immunol. 2006;7(1):33-39. (Pubitemid 41823866)
37. McHutchison JG, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580-593.
38. Heim MH. Interferon signaling. In: Clavien PA, Dufour JF, eds. Signaling Pathways in Liver Diseases. Berlin, Germany: Springer-Verlag; 2010:189-200.
39. Schoggins JW, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011;472(7344):481-485.
40. Metz P, et al. Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication. Hepatology. 2012;56(6):2082-2093.
41. Liu XY, Chen W, Wei B, Shan YF, Wang C. IFN-induced TPR protein IFIT3 potentiates antiviral signaling by bridging MAVS and TBK1. J Immunol. 2011;187(5):2559-2568.
42. Yoneyama M, et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol. 2005;175(5):2851-2858. (Pubitemid 41170502)
43. Versteeg GA, et al. The E3-ligase TRIM family of proteins regulates signaling pathways triggered by innate immune pattern-recognition receptors. Immunity. 2013;38(2):384-398.
44. Wilkins C, et al. IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology. 2013;57(2):461-469.
45. Everitt AR, et al. IFITM3 restricts the morbidity and mortality associated with influenza. Nature. 2012;484(7395):519-523.
46. Terenzi F, Hui DJ, Merrick WC, Sen GC. Distinct induction patterns and functions of two closely related interferon-inducible human genes, ISG54 and ISG56. J Biol Chem. 2006;281(45):34064-34071. (Pubitemid 46036616)
47. Marie I, Durbin JE, Levy DE. Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. EMBO J. 1998;17(22):6660-6669. (Pubitemid 28521799)
48. Marie I, Smith E, Prakash A, Levy DE. Phosphorylation-induced dimerization of interferon regulatory factor 7 unmasks DNA binding and a bipartite transactivation domain. Mol Cell Biol. 2000;20(23):8803-8814. (Pubitemid 32245913)
49. Wieland S, et al. Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver [published online ahead of print October 3, 2013]. Hepatology. doi:10.1002/hep.26770.
50. Pachkov M, Balwierz PJ, Arnold P, Ozonov E, van Nimwegen E. SwissRegulon, a database of genome-wide annotations of regulatory sites: recent updates. Nucleic Acids Res. 2013;41(Database issue):D214-D220.
51. Mikaelian I, Sergeant A. A general and fast method to generate multiple site directed mutations. Nucleic Acids Res. 1992;20(2):376.
52. R Development Core Team. R: A Language And Environment For Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.
53. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8(1):118-127. (Pubitemid 44906106)